Drug intelligence / Profile preview

CAN10

Development stage: Phase 1
Lead developer: Otsuka Holdings
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

CAN10 is a humanized monoclonal antibody developed by Cantargia that targets the interleukin-1 receptor accessory protein (IL1RAP). By binding to IL1RAP, CAN10 potently inhibits signaling from the pro-inflammatory cytokines IL-1, IL-33, and IL-36. This broad inhibition of inflammatory pathways is designed to address autoimmune and inflammatory diseases. CAN10 is currently in phase 1 clinical trials for plaque psoriasis and has orphan drug status in the US for systemic sclerosis. Preclinical studies have shown efficacy in models of myocarditis, systemic sclerosis, psoriasis, psoriatic arthritis, atherosclerosis, and peritonitis. The drug is administered intravenously or subcutaneously.

Targets

IL1RAP (Interleukin 1 receptor accessory protein)

Beyond the preview

Go deeper on CAN10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAN10.

Explore the full profile